Incontinence – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:33:02 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Incontinence – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Solifenacin, Mirabegron, and Their Combination for Treating Overactive Bladder and Daytime Urinary Incontinence in Children Aged 5 to 14 Years https://clinicaltrials.eu/trial/study-on-solifenacin-mirabegron-and-their-combination-for-treating-overactive-bladder-and-daytime-urinary-incontinence-in-children-aged-5-to-14-years/ Wed, 29 Apr 2026 14:30:03 +0000 https://clinicaltrials.eu/trial/study-on-solifenacin-mirabegron-and-their-combination-for-treating-overactive-bladder-and-daytime-urinary-incontinence-in-children-aged-5-to-14-years/ This clinical trial is focused on studying the effects of different treatments for children aged 5 to 14 years who have overactive bladder and daytime urinary incontinence. These conditions can cause frequent urges to urinate and accidental leakage of urine during the day. The study will explore the effectiveness of two medications, solifenacin and mirabegron, as well as a combination of both. Solifenacin is a medication that helps relax the bladder muscles, while mirabegron, also known by its code name YM178, works by helping the bladder hold more urine.

The purpose of the study is to evaluate how well these treatments work in reducing the number of wet days, which are days when accidental leakage occurs. Participants will be randomly assigned to receive either solifenacin, mirabegron, a combination of both, or a placebo. The study will last for a total of 18 weeks, with the main treatment period being 12 weeks. During this time, the number of wet days will be monitored to see how the treatments are working. The study will also look at other factors, such as changes in the severity of incontinence and the amount of urine the bladder can hold.

Throughout the study, participants will have regular check-ups to monitor their progress and any side effects. The study aims to provide valuable information on the best treatment options for children with overactive bladder and daytime urinary incontinence, potentially improving their quality of life. Participants will be closely monitored to ensure their safety and well-being during the trial.

]]> Study on Stopping Solifenacin and Mirabegron for Children with Daytime Urinary Incontinence https://clinicaltrials.eu/trial/study-on-stopping-solifenacin-and-mirabegron-for-children-with-daytime-urinary-incontinence/ Wed, 29 Apr 2026 14:30:01 +0000 https://clinicaltrials.eu/trial/study-on-stopping-solifenacin-and-mirabegron-for-children-with-daytime-urinary-incontinence/ This clinical trial is focused on studying daytime urinary incontinence in children. The trial will explore the effects of stopping medication treatment for this condition. The medications involved in the study are solifenacin succinate and mirabegron. Solifenacin succinate, also known by its code name YM-905, is a medication that helps relax the bladder by blocking certain receptors. Mirabegron, also known as YM178, works by activating specific receptors in the bladder to help it hold more urine.

The purpose of the study is to determine if stopping these medications suddenly or gradually affects the likelihood of the incontinence returning. Participants in the study will either stop taking their medication all at once or gradually reduce their dosage over time. The study will monitor the recurrence of incontinence over a period of up to 12 months. Additionally, the study will look for any symptoms that might occur when the medication is stopped.

Participants will be children who have been successfully treated for urinary incontinence with solifenacin and/or mirabegron. The study will track their progress and any changes in their condition after the medication is withdrawn. The goal is to better understand how to manage the discontinuation of these treatments in children who have achieved continence.

]]>